Share to: share facebook share twitter share wa share telegram print page

Fezakinumab

Fezakinumab
Monoclonal antibody
TypeWhole antibody
TargetIL-22
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6408H9873N1706O2016S44
Molar mass144479.04 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Fezakinumab is a human monoclonal antibody against interleukin-22,[1] designed for the treatment of psoriasis and rheumatoid arthritis.[2]

Research and development

Wyeth discovered and initially developed the drug, and clinical development continued after that company was acquired by Pfizer. Fezakinumab, in combination with methotrexate, completed a phase II trial in rheumatoid arthritis,[3] but data were not released. A small phase II trial of fezakinumab showed significant improvement in the Scoring Atopic Dermatitis (SCORAD) score for patients with severe atopic dermatitis.[4]

References

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab" (PDF). American Medical Association. Retrieved 2017-06-07.
  2. ^ "Pfizer Pipeline" (PDF). 28 February 2011. Archived from the original (PDF) on 2011-09-04. Retrieved 2012-09-25.
  3. ^ "Emerging Parenteral Biologic Therapies for Rheumatoid Arthritis". Living Medical eTextbook - Rheumatology - Projects In Knowledge. p. 4. Archived from the original on 24 January 2018. Retrieved 2017-06-07.
  4. ^ Richardson B. "Atopic dermatitis: fezakinumab shows benefit in severe disease". quantiamd.univadis.com. Aptus Health. Archived from the original on 25 January 2018. Retrieved 24 January 2018.
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.
Kembali kehalaman sebelumnya